Skip to main content
Menu
Revvity logo
Contact us

Loading...

US
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Login/Register here
Revvity web shop online account

Get exclusive pricing on all online purchases.

Login to your Revvity.com account for your account's pricing, easy re-ordering from favorites & order history, priority order processing, and dynamic order tracking.

Login Register
Revvity Omics portal accounts

Initiate a new order or access test status and results for clinical genomics or newborn screening services.

View login options
Breadcrumb
...
  • Home
  • Blog
  • Cancer
  • Considerations for engineering a successful knockout cell line generation.
Considerations for successful knockout cell line generation.

Blog

Cancer

Jan 17th 2025

2 min read

Considerations for engineering a successful knockout cell line generation.

Help us improve your Revvity blog experience!

Feedback

CRISPR-Cas9 has made it easier and faster to create an engineered cell line, giving rise to the popularity of this approach in various experimental areas, such as protein-protein interaction, hit validation, genomic functional analysis, and creation of disease models. Applications such as protein tagging also help enrich our understanding of particular gene targets.

Key considerations for engineering a knockout cell line

To precisely edit or knockout a genomic target, there are some key considerations to be taken into account.

  • Choice of cell line – What is the most suitable cell line to model a disease or test a gene’s functional effect? In addition to biological origin, you must consider the difficulty of delivery of CRISPR components, whether the cells can be enriched for targeted events, and the tolerance of the cells to the dilution steps necessary to generate a clonal population.
  • CRISPR-Cas9 reagent selection – In addition to selection of highly functional guide RNAs to create a double-strand break within your gene target, you will need to optimize the delivery of Cas9 nuclease to your cells for maximum efficiency. If you’re performing a knock-in (introduction of a SNP, fluorescent tag, or other alteration) the design of an oligo or plasmid donor is critical to experimental success.
  • Screening of clones – How amenable are your cells to dilution, and how many clones do you need to analyze to find those that are homozygous for the gene editing event? What method will you use to identify edited cells? This is potentially the most critical aspect of cell line development since the isolation and characterization is when your hard work in the CRISPR experiments will culminate.
  • Validation – Initial characterization of edited cells must be followed by more thorough validation, most often using protein-level methods (Western blot, immunofluorescence). The method(s) will be driven by the genomic alteration being made.

Alternatives to DIY cell lines

Many labs do not have the time or resources to develop their own cell lines. At Revvity, we offer a range of ready-to-go engineered cell lines to choose from. Alternatively, our expert preclinical services team can develop custom cell lines to your exact specifications, drawing on over a decade of experience in cell line engineering.

Find out more about our custom cell line engineering services or contact our team to discuss your needs.

Learn more

For research use only. Not for use in diagnostic procedures.

Help us improve your Revvity blog experience!

Feedback

Share this post:

  • Email
  • Facebook
  • Linkedin
  • Twitter

More Cancer posts

Scaling up oligonucleotide discovery: accelerating therapeutic lead identification from months to weeks.
Read
Cell-free DNA: dynamic regulation and NGS strategies for ultra-low-frequency variant detection.
Read
Good gut feelings about the health of microbial research.
Read

Questions?
We’re here to help.

Contact us
Revvity Logo

Loading...

    ©2025 Revvity - All rights reserved

    Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.